The cardiovascular continuum refined: A hypothesis

Blood Pressure

Volumn 19, Issue 5, 2010, Pages 273-277

  Volpe, Massimo ^a   Camm, John ^b   Coca, Antonio ^c   Unger, Thomas ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cardiovascular disease continuum; CV disease progression; Therapeutic strategies

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANDESARTAN; IRBESARTAN; LOSARTAN; PERINDOPRIL; SPIRONOLACTONE; VALSARTAN;

ALBUMIN BLOOD LEVEL; ARTERY DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DYSLIPIDEMIA; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; FIBROSIS; GLOMERULUS FILTRATION RATE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOTHESIS; INFLAMMATION; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SMOKING;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RISK;

EID: 77957093181     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.481072     Document Type: Review

References (23)

1. Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin - angiotensin - aldosterone system. J Am Soc Nephrol. 2006;17:S36-S43.
2. Bohm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: Data from i-search. J Hypertens. 2008;26:18-25.
3. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens. 2003;21: 1213-1220.
4. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: Association with incident coronary heart disease and death. Hypertension. 2005;46:33-37.
5. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202. (Pubitemid 40179960)
6. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
7. Ridker PM. Clinical application of c-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
8. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275-281.
9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195-2207
10. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110: 1103-1107.
11. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: The trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA. 2009;301:383-392.
12. Wilson PW; CDC; AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation. 2004;110:e568-e571.
13. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton- Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
14. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006;48:1733-1741.
15. Benjamin EJ, Levy D, Vaziri SM, D A gostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA. 1994;271:840-844.
16. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin ii receptor blockade reduces newonset atrial fibrillation and subsequent stroke compared to atenolol: The losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005;45: 712-719.
17. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:705-711. (Pubitemid 40282585)
18. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA; VALUE Trial Group. Reduced incidence of newonset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403-411.
19. Connolly S, Yusuf S, Budaj A, Camm J, Chrolavicius S, Commerford PJ, et al. Rationale and design of active: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J. 2006;151:1187 - 1193; results presented at ESC 2009.
20. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J. 2008;29:339-347.
21. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The Charm-preserved trial. Lancet. 2003;362: 777-781.
22. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.
23. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359:2456-2467.